Cqs Cayman Lp Lowers stake in Ariad Pharmaceuticals (ARIA)

Ariad Pharmaceuticals (ARIA) : Cqs Cayman Lp reduced its stake in Ariad Pharmaceuticals by 10.6% during the most recent quarter end. The investment management company now holds a total of 1,012,046 shares of Ariad Pharmaceuticals which is valued at $13,424,790 after selling 119,954 shares in Ariad Pharmaceuticals , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Ariad Pharmaceuticals makes up approximately 4.50% of Cqs Cayman Lp’s portfolio.

Other Hedge Funds, Including , Ahl Partners Llp added ARIA to its portfolio by purchasing 20,701 company shares during the most recent quarter which is valued at $274,599. Ariad Pharmaceuticals makes up approx 0.01% of Ahl Partners Llp’s portfolio.Elk Creek Partners reduced its stake in ARIA by selling 1,165,964 shares or 56.81% in the most recent quarter. The Hedge Fund company now holds 886,561 shares of ARIA which is valued at $10,434,823. Ariad Pharmaceuticals makes up approx 0.71% of Elk Creek Partners’s portfolio.Ifp Advisors Inc boosted its stake in ARIA in the latest quarter, The investment management firm added 29,000 additional shares and now holds a total of 82,970 shares of Ariad Pharmaceuticals which is valued at $736,359. Ariad Pharmaceuticals makes up approx 0.04% of Ifp Advisors Inc’s portfolio.California Public Employees Retirement System reduced its stake in ARIA by selling 22,700 shares or 6.43% in the most recent quarter. The Hedge Fund company now holds 330,200 shares of ARIA which is valued at $3,093,974. Ariad Pharmaceuticals makes up approx 0.01% of California Public Employees Retirement System’s portfolio.

Ariad Pharmaceuticals opened for trading at $13.85 and hit $14.08 on the upside on Monday, eventually ending the session at $14.06, with a gain of 1.22% or 0.17 points. The heightened volatility saw the trading volume jump to 60,22,110 shares. Company has a market cap of $2,730 M.

On the company’s financial health, Ariad Pharmaceuticals reported $-0.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Nov 7, 2016. Analyst had a consensus of $-0.18. The company had revenue of $46.02 million for the quarter, compared to analysts expectations of $42.80 million. The company’s revenue was up 58.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.29 EPS.

Many Wall Street Analysts have commented on Ariad Pharmaceuticals. Deutsche Bank Initiated Ariad Pharmaceuticals on Nov 3, 2016 to “Hold”, Price Target of the shares are set at $9.50.Ariad Pharmaceuticals was Downgraded by JMP Securities to ” Mkt Perform” on Oct 25, 2016. Ariad Pharmaceuticals was Downgraded by JP Morgan to ” Underweight” on Oct 24, 2016.

ARIAD Pharmaceuticals Inc. is a global oncology company. The Company is engaged in the discovery development and commercialization of small molecule drug indicated for the treatment of cancer. The Company’s product pipeline includes Iclusig (ponatinib) brigatinib (AP26113) AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI) which is approved in the United States Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788 is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Ariad Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Ariad Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.